| Entry |
|
|---|
| Name |
Infliximab (genetical recombination) (JAN);
Infliximab (USAN/INN);
Remicade (TN)
|
|---|
| Product |
|
|---|
| Activity |
|
|---|
| Remark |
Therapeutic category: ATC code: |
|---|
| Comment |
anti-TNF-alpha monoclonal antibody
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Structure map |
| Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
239 Miscellaneous
2399 Others
D02598 Infliximab (genetical recombination) (JAN); Infliximab (USAN/INN)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB02 Infliximab
D02598 Infliximab (genetical recombination) (JAN); Infliximab (USAN/INN)
USP drug classification [BR:br08302]
Immunological Agents
Immune Suppressants
Tumor Necrosis Factor (TNF) Blockers
Infliximab
D02598 Infliximab (genetical recombination) (JAN); Infliximab (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokines
TNF family
TNF-alpha [HSA:7124] [KO:K03156]
Infliximab [ATC:L04AB02]
D02598 Infliximab (genetical recombination) (JAN); Infliximab (USAN/INN)
 |
|---|
| Other DBs |
CAS: 170277-31-3 PubChem: DrugBank: NIKKAJI: |
|---|
